Relief Therapeutics Holding SA (SWX:RLF)
Switzerland
· Delayed Price · Currency is CHF 2.790
-0.035 (-1.25%)
Dec 5, 2025, 5:30 PM CET
SWX:RLF Revenue
Relief Therapeutics Holding had revenue of 1.22M CHF in the half year ending June 30, 2025, a decrease of -57.10%. This brings the company's revenue in the last twelve months to 4.05M, down -52.81% year-over-year. In the year 2024, Relief Therapeutics Holding had annual revenue of 8.42M with 39.52% growth.
Revenue (ttm)
4.05M
Revenue Growth
-52.81%
P/S Ratio
8.67
Revenue / Employee
144.79K
Employees
31
Market Cap
35.13M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 63.49B |
| Novartis AG | 44.95B |
| Lonza Group AG | 7.09B |
| Galderma Group AG | 3.73B |
| Alcon | 8.12B |
| Sandoz Group AG | 8.42B |
| Straumann Holding AG | 2.58B |
| Sonova Holding AG | 3.85B |
Relief Therapeutics Holding News
- 10 days ago - Relief Therapeutics Publishes Joint Deck Ahead Of NeuroX Merger; Stock Up - Nasdaq
- 21 days ago - Relief Therapeutics Shareholders Approve Business Combination with NeuroX - Accesswire
- 5 weeks ago - Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 - Accesswire
- 4 months ago - Relief Therapeutics Publishes 2025 Half-Year Report - Accesswire
- 4 months ago - Relief Therapeutics Advances Publication of 2025 Half-Year Report - Accesswire
- 4 months ago - Relief Therapeutics reports proposed business combination with NeuroX - Seeking Alpha
- 4 months ago - Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze - Accesswire
- 6 months ago - Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 - Accesswire